WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Estradiol Gel, 0.1%. It is the generic version of the Reference Listed Drug Divigel.
'The approval and launch of Estradiol Gel, 0.1%, mark an important milestone for ANI, as this is the first topical gel approved from our R&D and manufacturing site in New Jersey,' said Nikhil Lalwani, President and CEO of ANI.
The company noted that the current annual U.S. market for Estradiol Gel, 0.1%, is approximately $42.3 million, according to IQVIA.
For More Such Health News, visit rttnews.com.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX